Christopher H. Rassekh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christopher H. Rassekh has a total of 538 co-authors. Here are the top co-authors by number of shared publications:
Gregory S. Weinstein
Department of Otorhinolaryngology – Head and Neck Surgery, Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA
6 shared publications- Gregory S. Weinstein
Departments of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Philadelphia, Pennsylvania
6 shared publications - John Nicholas Lukens
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
6 shared publications - Alexander Lin
University of Pennsylvania Perelman School of Medicine, Department of Radiation Oncology, 3400 Civic Center Blvd, Philadelphia, PA 19104, United States
5 shared publications Ara A. Chalian
Department of Otorhinolaryngology – Head and Neck Surgery, Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA
5 shared publications- Karthik Rajasekaran
Department of Otolaryngology—Head and Neck Surgery University of Pennsylvania Philadelphia Pennsylvania USA
4 shared publications
Latest Publications
- Open Access
Head and Neck Paragangliomas: Overview of Institutional Experience
Head and neck paragangliomas (HNPGLs) are rare and have high rates of genetic mutations. We conducted a retrospective review of 187 patients with 296 PGLs diagnosed between 1974 and 2023. The mean age of diagnosis was 48.8 years (range 10 to 82) with 69.0% female and 26.5% patients with multiple PGLs. Among 119 patients undergoing genetic testing, 70 (58.8%) patients had mutations, with SDHB (30) and SDHD (26) being the most common. The rates of metastasis and recurrence were higher among patients with SDHB mutations or SDHD mutations associated with multiple PGLs. Metabolic evaluation showed elevated plasma dopamine levels were the most common derangements in HNPGL. MRI and CT were the most common anatomic imaging modalities and DOTATATE was the most common functional scan used in this cohort. Most patients (81.5%) received surgery as the primary definitive treatment, while 22.5% patients received radiation treatment, mostly as an adjuvant therapy or for surgically challenging or inoperable cases. Systemic treatment was rarely used in our cohort. Our single-center experience highlights the need for referral for genetic testing and metabolic evaluation and for a team-based approach to improve the clinical outcomes of patients with HNPGLs.
Open AccessHead and Neck Paragangliomas: Overview of Institutional Experience
Head and neck paragangliomas (HNPGLs) are rare and have high rates of genetic mutations. We conducted a retrospective review of 187 patients with 296 PGLs diagnosed between 1974 and 2023. The mean age of diagnosis was 48.8 years (range 10 to 82) with 69.0% female and 26.5% patients with multiple PGLs. Among 119 patients undergoing genetic testing, 70 (58.8%) patients had mutations, with SDHB (30) and SDHD (26) being the most common. The rates of metastasis and recurrence were higher among patients with SDHB mutations or SDHD mutations associated with multiple PGLs. Metabolic evaluation showed elevated plasma dopamine levels were the most common derangements in HNPGL. MRI and CT were the most common anatomic imaging modalities and DOTATATE was the most common functional scan used in this cohort. Most patients (81.5%) received surgery as the primary definitive treatment, while 22.5% patients received radiation treatment, mostly as an adjuvant therapy or for surgically challenging or inoperable cases. Systemic treatment was rarely used in our cohort. Our single-center experience highlights the need for referral for genetic testing and metabolic evaluation and for a team-based approach to improve the clinical outcomes of patients with HNPGLs.
- Open Access
- 5 September 2023
- Published by Georg Thieme Verlag KG in Journal of Neurological Surgery Reports
- Vol. 84 (04) , e124-e128
CIC-DUX4 Sarcoma Involving the Skull Base: A Rare Presentation and Review of the Literature
Background CIC-DUX4 sarcoma is a rare, aggressive tumor that is difficult to diagnose. Although it is closely related to Ewing's sarcoma, each is a distinct pathologic entity and both have been previously reported in the skin, lymph nodes, and viscera. We report the first description of CIC-DUX4 involving the posterior cranial fossa and review the distinctive symptomatology, morphology, immunoprofile, and genetic signature that differentiate this rare tumor. Case Report A 32-year-old man presented with an enlarging right lateral neck mass, progressive hoarseness, and orofacial pain. Biopsy revealed a high-grade undifferentiated malignant neoplasm. Imaging demonstrated an 8-cm mass in the right neck extending to the skull base and abutting the carotid sheath, in addition to pulmonary nodules and pelvic lymphadenopathy. Despite initial response to chemotherapy, he experienced disease progression and underwent surgical resection, radical neck dissection, and brachytherapy. Definitive pathologic diagnosis was achieved with next-generation sequencing. Within weeks of treatment, he developed symptoms reflecting progression of disease involving the neck, posterior cranial fossa, and lung. Adjuvant chemotherapy was planned, but the patient succumbed to his disease prior to initiation of further therapy. Conclusion CIC-DUX4 sarcomas are uncommon and can progress rapidly. Diagnosis requires either fluorescence in situ hybridization or next-generation sequencing. Due to its rarity, there is no standard-of-care treatment for this tumor and further investigations are needed to understand disease behavior and develop targeted therapeutic modalities.
- 5 September 2023
- Published by Georg Thieme Verlag KG in Journal of Neurological Surgery Reports
- Vol. 84 (04) , e124-e128
Open AccessCIC-DUX4 Sarcoma Involving the Skull Base: A Rare Presentation and Review of the Literature
Background CIC-DUX4 sarcoma is a rare, aggressive tumor that is difficult to diagnose. Although it is closely related to Ewing's sarcoma, each is a distinct pathologic entity and both have been previously reported in the skin, lymph nodes, and viscera. We report the first description of CIC-DUX4 involving the posterior cranial fossa and review the distinctive symptomatology, morphology, immunoprofile, and genetic signature that differentiate this rare tumor. Case Report A 32-year-old man presented with an enlarging right lateral neck mass, progressive hoarseness, and orofacial pain. Biopsy revealed a high-grade undifferentiated malignant neoplasm. Imaging demonstrated an 8-cm mass in the right neck extending to the skull base and abutting the carotid sheath, in addition to pulmonary nodules and pelvic lymphadenopathy. Despite initial response to chemotherapy, he experienced disease progression and underwent surgical resection, radical neck dissection, and brachytherapy. Definitive pathologic diagnosis was achieved with next-generation sequencing. Within weeks of treatment, he developed symptoms reflecting progression of disease involving the neck, posterior cranial fossa, and lung. Adjuvant chemotherapy was planned, but the patient succumbed to his disease prior to initiation of further therapy. Conclusion CIC-DUX4 sarcomas are uncommon and can progress rapidly. Diagnosis requires either fluorescence in situ hybridization or next-generation sequencing. Due to its rarity, there is no standard-of-care treatment for this tumor and further investigations are needed to understand disease behavior and develop targeted therapeutic modalities.
- Open Access
- 18 August 2022
- Published by Springer Nature in Cureus
- Vol. 14 (8) , e28147
Contemporary Review of Submandibular Gland Sialolithiasis and Surgical Management Options
One of the most common disorders of the salivary glands is obstructive sialolithiasis. Salivary gland obstruction is important to address, as it can significantly impact patient quality of life and can progress to extensive cellulitis and abscess formation if left untreated. For small and accessible stones, conservative therapies often produce satisfactory outcomes. Operative management should be considered when stones are inaccessible or larger in size, and options include sialendoscopy, laser lithotripsy, extracorporeal shockwave lithotripsy, transoral surgery, and submandibular gland adenectomy. Robotic approaches are also becoming increasingly used for submandibular stone management. The purpose of this review is to summarize the modern-day management of submandibular gland obstructive sialolithiasis with an emphasis on operative treatment modalities. A total of 77 articles were reviewed from PubMed and Embase databases, specifically looking at the pathophysiology, clinical presentation, diagnosis, and management of submandibular sialolithiasis.
- 18 August 2022
- Published by Springer Nature in Cureus
- Vol. 14 (8) , e28147
Open AccessContemporary Review of Submandibular Gland Sialolithiasis and Surgical Management Options
One of the most common disorders of the salivary glands is obstructive sialolithiasis. Salivary gland obstruction is important to address, as it can significantly impact patient quality of life and can progress to extensive cellulitis and abscess formation if left untreated. For small and accessible stones, conservative therapies often produce satisfactory outcomes. Operative management should be considered when stones are inaccessible or larger in size, and options include sialendoscopy, laser lithotripsy, extracorporeal shockwave lithotripsy, transoral surgery, and submandibular gland adenectomy. Robotic approaches are also becoming increasingly used for submandibular stone management. The purpose of this review is to summarize the modern-day management of submandibular gland obstructive sialolithiasis with an emphasis on operative treatment modalities. A total of 77 articles were reviewed from PubMed and Embase databases, specifically looking at the pathophysiology, clinical presentation, diagnosis, and management of submandibular sialolithiasis.
- 10 March 2022
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 128 (6) , 726-727
A rare case of allergic sialadenitis successfully treated with dupilumab and sialendoscopy
- 10 March 2022
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 128 (6) , 726-727
A rare case of allergic sialadenitis successfully treated with dupilumab and sialendoscopy
- 1 March 2022
- Published by Elsevier in Oral Oncology
- Vol. 127, 105798
A benchmark for oncologic outcomes and model for lethal recurrence risk after transoral robotic resection of HPV-related oropharyngeal cancers
- 1 March 2022
- Published by Elsevier in Oral Oncology
- Vol. 127, 105798
A benchmark for oncologic outcomes and model for lethal recurrence risk after transoral robotic resection of HPV-related oropharyngeal cancers
- 1 December 2021
- Published by Elsevier in Oral Oncology
- Vol. 123, 105570
Sex-based differences in outcomes among surgically treated patients with HPV-related oropharyngeal squamous cell carcinoma
- 1 December 2021
- Published by Elsevier in Oral Oncology
- Vol. 123, 105570
Sex-based differences in outcomes among surgically treated patients with HPV-related oropharyngeal squamous cell carcinoma
- 1 May 2021
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 42 (3) , 102917
COVID-19 survivorship: How otolaryngologist-head and neck surgeons can restore quality of life after critical illness
- 1 May 2021
- Published by Elsevier in American Journal of Otolaryngology
- Vol. 42 (3) , 102917
COVID-19 survivorship: How otolaryngologist-head and neck surgeons can restore quality of life after critical illness
- 16 December 2020
- Published by Wiley in Head & Neck
- Vol. 43 (4) , 1128-1141
Increased rate of recurrence and high rate of salvage in patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma with adverse features treated with primary surgery without recommended adjuvant therapy
Background: Some patients with human papillomavirus (HPV)–associated oropharyngeal squamous cell carcinoma (OPSCC) do not receive guideline‐recommended postoperative radiation therapy (PORT) following primary transoral robotic surgery (TORS).Methods: Three‐hundred and sixty‐four patients with treatment‐naïve, HPV‐associated OPSCC were recommended to receive PORT based on clinicopathological features following TORS. Patients were stratified based on if they received PORT. Oncologic outcomes were compared.Results: The 3‐year locoregional failure (LRF) was 32% in patients who did not receive PORT and 4% in patients who received PORT (P < .001). Despite increased LRF, avoiding PORT was not associated with increased 3‐year distant metastasis rates (8% vs 4%, P = .56) or worse 3‐year survival (95% vs 98%, P = .34). Recurrences in the surgery alone cohort varied between local and regional sites and were often successfully salvaged.Conclusions: Patients with HPV‐associated OPSCC who do not receive indicated PORT have an increased risk of LRF but similar survival due to high salvage rates.
- 16 December 2020
- Published by Wiley in Head & Neck
- Vol. 43 (4) , 1128-1141
Increased rate of recurrence and high rate of salvage in patients with human papillomavirus–associated oropharyngeal squamous cell carcinoma with adverse features treated with primary surgery without recommended adjuvant therapy
Background: Some patients with human papillomavirus (HPV)–associated oropharyngeal squamous cell carcinoma (OPSCC) do not receive guideline‐recommended postoperative radiation therapy (PORT) following primary transoral robotic surgery (TORS).Methods: Three‐hundred and sixty‐four patients with treatment‐naïve, HPV‐associated OPSCC were recommended to receive PORT based on clinicopathological features following TORS. Patients were stratified based on if they received PORT. Oncologic outcomes were compared.Results: The 3‐year locoregional failure (LRF) was 32% in patients who did not receive PORT and 4% in patients who received PORT (P < .001). Despite increased LRF, avoiding PORT was not associated with increased 3‐year distant metastasis rates (8% vs 4%, P = .56) or worse 3‐year survival (95% vs 98%, P = .34). Recurrences in the surgery alone cohort varied between local and regional sites and were often successfully salvaged.Conclusions: Patients with HPV‐associated OPSCC who do not receive indicated PORT have an increased risk of LRF but similar survival due to high salvage rates.
- 1 December 2020
- Published by Elsevier in Otolaryngologic Clinics of North America
- Vol. 53 (6) , 1051-1064
Robotic Management of Salivary Glands
- 1 December 2020
- Published by Elsevier in Otolaryngologic Clinics of North America
- Vol. 53 (6) , 1051-1064
Robotic Management of Salivary Glands
- 11 June 2020
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 274 (6) , e778-e779
Response to the Comment on: Tracheotomy in Ventilated Patients With COVID-19
An abstract is unavailable. This article is available as a PDF only.
- 11 June 2020
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 274 (6) , e778-e779
Response to the Comment on: Tracheotomy in Ventilated Patients With COVID-19
An abstract is unavailable. This article is available as a PDF only.